HIF1AN抗体;HIF1AN Antibody—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: 231 cells, Primary antibody: P11765(HIF1AN Antibody) at dilution 1/250, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 20 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P11765(HIF1AN Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P11765(HIF1AN Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The HIF1AN antibody is a crucial tool in studying hypoxia-inducible factor 1-alpha inhibitor (HIF1AN), a key enzyme involved in oxygen-sensing pathways. HIF1AN, also known as factor inhibiting HIF-1 (FIH-1), hydroxylates the asparagine residue in the C-terminal transactivation domain of HIF-1α, suppressing its interaction with transcriptional coactivators like p300/CBP. This post-translational modification inhibits HIF-1α-mediated gene expression under normoxic conditions, regulating cellular responses to hypoxia. Dysregulation of HIF1AN is linked to cancer, cardiovascular diseases, and metabolic disorders, making it a research focus in tumor angiogenesis, ischemic adaptation, and metabolic reprogramming.

The HIF1AN antibody enables detection and quantification of HIF1AN protein levels in various experimental models (e.g., Western blot, immunohistochemistry, immunofluorescence). Researchers use it to explore HIF1AN's interaction with HIF-1α, its subcellular localization, and its role in modulating hypoxia-responsive genes (e.g., VEGF, GLUT1). Validated antibodies are essential for distinguishing HIF1AN from related hydroxylases and confirming its expression changes under hypoxia or genetic manipulation (e.g., CRISPR/Cas9 knockout). Both polyclonal and monoclonal variants exist, with specificity verified through knockout cell lines or peptide blocking assays. Its applications span basic research, drug development, and biomarker studies in diseases involving oxygen homeostasis.